Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Association among Complement Factor H Autoantibodies, Deletions of CFHR, and the Risk of Atypical Hemolytic Uremic Syndrome.

Jiang H, Fan MN, Yang M, Lu C, Zhang M, Liu XH, Ma L.

Int J Environ Res Public Health. 2016 Dec 5;13(12). pii: E1209.

2.

The Genetics of Ultra-Rare Renal Disease.

Muff-Luett M, Nester CM.

J Pediatr Genet. 2016 Mar;5(1):33-42. doi: 10.1055/s-0036-1572515. Review.

3.

Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea.

Cheong HI, Jo SK, Yoon SS, Cho H, Kim JS, Kim YO, Koo JR, Park Y, Park YS, Shin JI, Yoo KH, Oh D.

J Korean Med Sci. 2016 Oct;31(10):1516-28. doi: 10.3346/jkms.2016.31.10.1516.

4.

Oxidative stress, innate immunity, and age-related macular degeneration.

Shaw PX, Stiles T, Douglas C, Ho D, Fan W, Du H, Xiao X.

AIMS Mol Sci. 2016;3(2):196-221.

5.

A novel quantitative hemolytic assay coupled with restriction fragment length polymorphisms analysis enabled early diagnosis of atypical hemolytic uremic syndrome and identified unique predisposing mutations in Japan.

Yoshida Y, Miyata T, Matsumoto M, Shirotani-Ikejima H, Uchida Y, Ohyama Y, Kokubo T, Fujimura Y.

PLoS One. 2015 May 7;10(5):e0124655. doi: 10.1371/journal.pone.0124655.

6.

The major autoantibody epitope on factor H in atypical hemolytic uremic syndrome is structurally different from its homologous site in factor H-related protein 1, supporting a novel model for induction of autoimmunity in this disease.

Bhattacharjee A, Reuter S, Trojnár E, Kolodziejczyk R, Seeberger H, Hyvärinen S, Uzonyi B, Szilágyi Á, Prohászka Z, Goldman A, Józsi M, Jokiranta TS.

J Biol Chem. 2015 Apr 10;290(15):9500-10. doi: 10.1074/jbc.M114.630871.

7.

Atypical hemolytic uremic syndrome post-kidney transplantation: two case reports and review of the literature.

Alasfar S, Alachkar N.

Front Med (Lausanne). 2014 Dec 12;1:52. doi: 10.3389/fmed.2014.00052. Review.

8.

Factor h: a complement regulator in health and disease, and a mediator of cellular interactions.

Kopp A, Hebecker M, Svobodová E, Józsi M.

Biomolecules. 2012 Feb 7;2(1):46-75. doi: 10.3390/biom2010046.

9.

Atypical hemolytic uremic syndrome.

Kavanagh D, Goodship TH, Richards A.

Semin Nephrol. 2013 Nov;33(6):508-30. doi: 10.1016/j.semnephrol.2013.08.003. Review.

10.

Determining the population frequency of the CFHR3/CFHR1 deletion at 1q32.

Holmes LV, Strain L, Staniforth SJ, Moore I, Marchbank K, Kavanagh D, Goodship JA, Cordell HJ, Goodship TH.

PLoS One. 2013 Apr 16;8(4):e60352. doi: 10.1371/journal.pone.0060352.

11.

Recent insights into C3 glomerulopathy.

Barbour TD, Pickering MC, Cook HT.

Nephrol Dial Transplant. 2013 Jul;28(7):1685-93. doi: 10.1093/ndt/gfs430. Review.

12.

Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype.

Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V, Rodriguez de Cordoba S, Pinto S, Goodship TH, Alberti M, Ribes D, Valoti E, Remuzzi G, Noris M; European Working Party on Complement Genetics in Renal Diseases..

J Am Soc Nephrol. 2013 Feb;24(3):475-86. doi: 10.1681/ASN.2012090884.

13.

Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome.

Hofer J, Janecke AR, Zimmerhackl LB, Riedl M, Rosales A, Giner T, Cortina G, Haindl CJ, Petzelberger B, Pawlik M, Jeller V, Vester U, Gadner B, van Husen M, Moritz ML, Würzner R, Jungraithmayr T; German-Austrian HUS Study Group..

Clin J Am Soc Nephrol. 2013 Mar;8(3):407-15. doi: 10.2215/CJN.01260212.

14.

Factor H autoantibodies and deletion of Complement Factor H-Related protein-1 in rheumatic diseases in comparison to atypical hemolytic uremic syndrome.

Foltyn Zadura A, Zipfel PF, Bokarewa MI, Sturfelt G, Jönsen A, Nilsson SC, Hillarp A, Saxne T, Trouw LA, Blom AM.

Arthritis Res Ther. 2012 Aug 15;14(4):R185. doi: 10.1186/ar4016.

15.

Thrombotic microangiopathy and associated renal disorders.

Barbour T, Johnson S, Cohney S, Hughes P.

Nephrol Dial Transplant. 2012 Jul;27(7):2673-85. doi: 10.1093/ndt/gfs279. Review.

16.

Atypical hemolytic uremic syndrome.

Loirat C, Frémeaux-Bacchi V.

Orphanet J Rare Dis. 2011 Sep 8;6:60. doi: 10.1186/1750-1172-6-60. Review.

17.

Hemolytic uremic syndrome: new developments in pathogenesis and treatment.

Boyer O, Niaudet P.

Int J Nephrol. 2011;2011:908407. doi: 10.4061/2011/908407.

18.

Atypical hemolytic uremic syndrome and mutation analysis of factor H gene in two Tunisian families.

Habibi I, Sfar I, Ben Alaya W, Methlouthi J, Ayadi A, Brahim M, Blouin J, Dhagbouj R, Ben Rhomdhane T, Makhlouf M, Aouadi H, Ayed-Jendoubi S, Fremeaux-Bacchi V, Sfar T, Ben Abdallah T, Ayed K, Gorgi Y.

Int J Nephrol Renovasc Dis. 2010;3:85-92.

19.

Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome.

Dragon-Durey MA, Sethi SK, Bagga A, Blanc C, Blouin J, Ranchin B, André JL, Takagi N, Cheong HI, Hari P, Le Quintrec M, Niaudet P, Loirat C, Fridman WH, Frémeaux-Bacchi V.

J Am Soc Nephrol. 2010 Dec;21(12):2180-7. doi: 10.1681/ASN.2010030315.

20.

Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis.

Gale DP, de Jorge EG, Cook HT, Martinez-Barricarte R, Hadjisavvas A, McLean AG, Pusey CD, Pierides A, Kyriacou K, Athanasiou Y, Voskarides K, Deltas C, Palmer A, Frémeaux-Bacchi V, de Cordoba SR, Maxwell PH, Pickering MC.

Lancet. 2010 Sep 4;376(9743):794-801. doi: 10.1016/S0140-6736(10)60670-8.

Supplemental Content

Support Center